Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Interest & Investment Income: 2019-2024

Historic Interest & Investment Income for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to $14.0 million.

  • Centessa Pharmaceuticals' Interest & Investment Income rose 12.72% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 72.50%. This contributed to the annual value of $14.0 million for FY2024, which is 33.79% up from last year.
  • Centessa Pharmaceuticals' Interest & Investment Income amounted to $14.0 million in FY2024, which was up 33.79% from $10.5 million recorded in FY2023.
  • Centessa Pharmaceuticals' 5-year Interest & Investment Income high stood at $14.0 million for FY2024, and its period low was -$1.2 million during FY2021.
  • Its 3-year average for Interest & Investment Income is $8.2 million, with a median of $10.5 million in 2023.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Interest & Investment Income tumbled by 1,623.53% in 2021, and later soared by 4,193.44% in 2023.
  • Centessa Pharmaceuticals' Interest & Investment Income (Yearly) stood at -$68,000 in 2020, then slumped by 1,623.53% to -$1.2 million in 2021, then spiked by 120.82% to $244,000 in 2022, then spiked by 4,193.44% to $10.5 million in 2023, then soared by 33.79% to $14.0 million in 2024.